baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

BAVARIAN NORDIC AS/ DK0015998017 /

03/06/2024 17:32:21	Chg. +0.13	Volume	Bid17:32:21	Ask17:32:21	High	Low
24.69EUR	+0.53%	0 Turnover: -	-Bid Size: -	-Ask Size: -	25.01	24.69

GlobeNewswire 31/05 Bavarian Nordic Submits Supplemental BLA Seeking U.S. FDA Approval of Freeze-Dried Formulation of Sm...

GlobeNewswire 29/04 Bavarian Nordic Initiates Rolling Submission of Biologics License Application with FDA for its Chiku...

GlobeNewswire 02/04 Bavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.S.

GlobeNewswire 23/02 Bavarian Nordic’s Chikungunya Vaccine Candidate Granted Accelerated Assessment by European Medicines...

GlobeNewswire 08/11/2023 Emergent BioSolutions Reports Third Quarter 2023 Financial Results

TeleTrader 19/08/2022 EU makes monkeypox vaccine more available

TeleTrader 18/08/2022 WH announces new strategies against monkeypox

TeleTrader 30/07/2022 Spain confirms second monkeypox death

TeleTrader 29/07/2022 Spain confirms Europe's first monkeypox death

TeleTrader 25/07/2022 Monkeypox vaccine approved by EU

TeleTrader 22/07/2022 EMA gives preliminary approval to monkeypox jab

GlobeNewswire 21/03/2022 Bavarian Nordic Announces License and Supply Agreement with Nuance Pharma on the Development and Com...

GlobeNewswire 28/02/2022 Bavarian Nordic Reports Additional Positive Phase 2 Results for its COVID-19 Vaccine Candidate Ahead...

GlobeNewswire 14/02/2022 Bavarian Nordic Announces Breakthrough Therapy Designation for its RSV Vaccine Candidate for the Pre...

GlobeNewswire 06/12/2021 Bavarian Nordic Commits to Initiating Phase 3 Trial of RSV Vaccine Candidate and to Strengthening it...

GlobeNewswire 05/12/2021 Bavarian Nordic Reports Positive Topline Phase 2 Results for its COVID-19 Vaccine Candidate

GlobeNewswire 01/09/2021 Bavarian Nordic Reports Positive Results from Human Challenge Trial of its RSV Vaccine Candidate

GlobeNewswire 23/08/2021 Bavarian Nordic Receives Funding from the Danish Ministry of Health to Advance the Development of CO...

GlobeNewswire 23/08/2021 Bavarian Nordic Initiates Phase 2 Clinical Trial of COVID-19 Booster Vaccine

GlobeNewswire 09/08/2021 Bavarian Nordic Reports Initial Results from First-in-Human Trial of COVID-19 Vaccine

GlobeNewswire 11/06/2021 Bavarian Nordic Assists Public Health England in Response to New Cases of Monkeypox

GlobeNewswire 08/03/2021 Bavarian Nordic Reports Encouraging Preclinical Data for COVID-19 Vaccine Candidate Ahead of First-i...

GlobeNewswire 16/12/2020 Bavarian Nordic Secures Second Part of Smallpox Vaccine Order from the U.S. Government

GlobeNewswire 24/08/2020 Bavarian Nordic Announces Positive Topline Results from Phase 3 Clinical Study of Freeze-dried Small...

GlobeNewswire 22/07/2020 Bavarian Nordic and AdaptVac Sign Final License Agreement on COVID-19 Vaccine

BAVARIAN NORDIC AS/ DK0015998017 /

If you wish to receive reply to your feedback, please provide your email address.